CLSI C52 A2 : 2ED 2007

Abstract
Committee Membership
Foreword
1 Scope
2 Introduction
3 Standard Precautions
4 Terminology
  4.1 Definitions
  4.2 Acronyms
5 Clinical Testing
  5.1 Applicable Drugs
  5.2 Populations to Be Tested
  5.3 Laboratory Personnel
  5.4 Drug Testing Programs
6 Preanalytical Phase
  6.1 Drug Testing Practice
  6.2 Specimen Characteristics
7 Analytical Phase - Analysis of Specimens
  7.1 Typical Analytes
  7.2 Assessment of Specimen Quality/Detection of Specimen
       Adulteration
  7.3 Initial Screening Tests
  7.4 Validation Tests
  7.5 Confirmatory Tests
  7.6 Sample Storage
  7.7 External Quality Assurance and Quality Control/Quality
       Assessment
8 Postanalytical Phase
  8.1 Drug Testing
  8.2 Serum Drug Testing
  8.3 Postanalytical Aspects
9 Forensic Drug Testing
  9.1 Applicable Abused Drugs
  9.2 Populations Tested
  9.3 Quality Control
  9.4 Laboratory Personnel
  9.5 Forensic Specimen Collection
  9.6 Forensic Urine Specimens
  9.7 Specimen Integrity
  9.8 Shipment to the Testing Laboratory
  9.9 Chain-of-Custody/Laboratory Request (Invoice) Form
  9.10 Specimen Handling
  9.11 Specimens, Split Samples, and Aliquots
  9.12 Forensic Controls
  9.13 Specimen Storage
References
Additional References
Appendix (Part 1). Example Chain-of-Custody Form
Appendix (Part 2). Instructions for Example Chain-of-Custody
                   Form
Summary of Delegate Comments and Working Group Responses
The Quality Management System Approach
Related CLSI/NCCLS Publications

Specifies drug testing in the clinical laboratory, both for clinical and forensic purposes, and pertains to both drugs of abuse and other drugs normally encountered and analyzed by hospital laboratories.